Outcomes of Focal Ablation for Prostate Cancer

Status Not yet recruiting

Clinical Trial Summary

Clinical Trial Description

This study will be designed to define the efficacy and safety of ablative therapies in the management of localized prostate cancer and comprehensively evaluate quality of life outcomes and oncologic control following treatment. There are several commercially available standard of care treatments available for local therapy of the prostate. Ablative therapies may be delivered via a whole gland or focal approach by systems including cryoablation (CA), brachytherapy, irreversible electroporation (IRE), high intensity focused ultrasound (HIFU), MRI-guided transurethral ultrasound ablation (TULSA) procedure or future novel prostate ablation systems. These are single, outpatient treatments lasting between 2-4 hours and include treatment planning and energy delivery under guidance and are either administered via transperineally approach (cryoablation, IRE, brachytherapy) or via the urethral (TULSA-Pro) or rectum (HIFU). This study protocol will not include experimental therapy. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05478694
Study type	Interventional
Source	University of Texas Southwestern Medical Center
Contact	Sonobia Garrett
Phone	214/645-8482
Email	[email protected]
Status	Not yet recruiting
Phase	Phase 2
Start date	September 2022
Completion date	August 2026

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05156424` - A Comparison of Aerobic and Resistance Exercise to Counteract Treatment Side Effects in Men With Prostate Cancer	Phase 1/Phase 2
Recruiting	`NCT04081636` - Prostate Biopsy, Transrectal vs. Transperineal: Efficacy and Complications	N/A
Completed	`NCT03177759` - Living With Prostate Cancer (LPC)
Recruiting	`NCT04742361` - Efficacy of [18F]PSMA-1007 PET/CT in Patients With Biochemial Recurrent Prostate Cancer	Phase 3
Recruiting	`NCT04400656` - PROState Pathway Embedded Comparative Trial
Completed	`NCT02282644` - Individual Phenotype Analysis in Patients With Castration-Resistant Prostate Cancer With CellSearch® and Flow Cytometry	N/A
Recruiting	`NCT04838626` - Study of Diagnostic Performance of [18F]CTT1057 for PSMA-positive Tumors Detection	Phase 2/Phase 3
Recruiting	`NCT03101176` - Multiparametric Ultrasound Imaging in Prostate Cancer	N/A
Completed	`NCT03290417` - Correlative Analysis of the Genomics of Vitamin D and Omega-3 Fatty Acid Intake in Prostate Cancer	N/A
Active, not recruiting	`NCT00341939` - Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
Completed	`NCT01497925` - Ph 1 Trial of ADI-PEG 20 Plus Docetaxel in Solid Tumors With Emphasis on Prostate Cancer and Non-Small Cell Lung Cancer	Phase 1
Recruiting	`NCT03679819` - Single-center Trial for the Validation of High-resolution Transrectal Ultrasound (Exact Imaging Scanner ExactVu) for the Detection of Prostate Cancer
Active, not recruiting	`NCT03554317` - COMbination of Bipolar Androgen Therapy and Nivolumab	Phase 2
Completed	`NCT03271502` - Effect of Anesthesia on Optic Nerve Sheath Diameter in Patients Undergoing Robot-assisted Laparoscopic Prostatectomy	N/A
Active, not recruiting	`NCT00499421` - Evaluation of Intraprostatic Fiducial Markers For External Beam Radiation Therapy
Not yet recruiting	`NCT04887935` - Neoadjuvant SGLT2 Inhibition in High-Risk Localized Prostate Cancer	Phase 1
Not yet recruiting	`NCT05046782` - Abbreviated Biparametric MRI (RSI + T2WI) for Prostate Cancer Detection: Correlation With Histopathology	Phase 2
Not yet recruiting	`NCT05035732` - RRPC Axumin PETMRI	N/A
Recruiting	`NCT04838613` - Study of Diagnostic Performance of [18F]CTT1057 in BCR	Phase 3
Recruiting	`NCT05019846` - SRT Versus SRT+ADT in Prostate Cancer	Phase 3